These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 15389794)

  • 1. New epitope peptides derived from parathyroid hormone-related protein which have the capacity to induce prostate cancer-reactive cytotoxic T lymphocytes in HLA-A2+ prostate cancer patients.
    Yao A; Harada M; Matsueda S; Ishihara Y; Shomura H; Takao Y; Noguchi M; Matsuoka K; Hara I; Kamidono S; Itoh K
    Prostate; 2005 Feb; 62(3):233-42. PubMed ID: 15389794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A parathyroid-hormone-related-protein (PTH-rP)-specific cytotoxic T cell response induced by in vitro stimulation of tumour-infiltrating lymphocytes derived from prostate cancer metastases, with epitope peptide-loaded autologous dendritic cells and low-dose IL-2.
    Correale P; Micheli L; Vecchio MT; Sabatino M; Petrioli R; Pozzessere D; Marsili S; Giorgi G; Lozzi L; Neri P; Francini G
    Br J Cancer; 2001 Nov; 85(11):1722-30. PubMed ID: 11742494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two proliferation-related proteins, TYMS and PGK1, could be new cytotoxic T lymphocyte-directed tumor-associated antigens of HLA-A2+ colon cancer.
    Shichijo S; Azuma K; Komatsu N; Ito M; Maeda Y; Ishihara Y; Itoh K
    Clin Cancer Res; 2004 Sep; 10(17):5828-36. PubMed ID: 15355913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prostate stem cell antigen-derived peptide immunogenic in HLA-A24- prostate cancer patients.
    Matsueda S; Yao A; Ishihara Y; Ogata R; Noguchi M; Itoh K; Harada M
    Prostate; 2004 Aug; 60(3):205-13. PubMed ID: 15176050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy.
    Machlenkin A; Paz A; Bar Haim E; Goldberger O; Finkel E; Tirosh B; Volovitz I; Vadai E; Lugassy G; Cytron S; Lemonnier F; Tzehoval E; Eisenbach L
    Cancer Res; 2005 Jul; 65(14):6435-42. PubMed ID: 16024648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.
    Bellone S; Anfossi S; O'Brien TJ; Cannon MJ; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    Cancer; 2009 Feb; 115(4):800-11. PubMed ID: 19117353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New peptides of the polycomb group protein enhancer of zeste homolog 2 with the potential to induce cancer-reactive cytotoxic T lymphocytes in human leukocyte antigen-A2+ prostate cancer patients.
    Itoh Y; Komohara Y; Komatsu N; Minami T; Saito K; Noguchi M; Itoh K; Harada M
    Oncol Rep; 2007 Nov; 18(5):1231-7. PubMed ID: 17914578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of antitumor cytotoxic T lymphocytes from the peripheral blood mononuclear cells of cancer patients using HLA-A2-restricted MAGE-3 peptide in vitro.
    Fujie T; Tanaka F; Mori M; Takesako K; Sugimachi K; Akiyoshi T
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2425-30. PubMed ID: 9815643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma.
    Komori H; Nakatsura T; Senju S; Yoshitake Y; Motomura Y; Ikuta Y; Fukuma D; Yokomine K; Harao M; Beppu T; Matsui M; Torigoe T; Sato N; Baba H; Nishimura Y
    Clin Cancer Res; 2006 May; 12(9):2689-97. PubMed ID: 16675560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High frequency of prostate antigen-directed T cells in cancer patients compared to healthy age-matched individuals.
    Forsberg O; Carlsson B; Malmström PU; Ullenhag G; Tötterman TH; Essand M
    Prostate; 2009 Jan; 69(1):70-81. PubMed ID: 18814178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate-related antigen-derived new peptides having the capacity of inducing prostate cancer-reactive CTLs in HLA-A2+ prostate cancer patients.
    Harada M; Matsueda S; Yao A; Ogata R; Noguchi M; Itoh K
    Oncol Rep; 2004 Sep; 12(3):601-7. PubMed ID: 15289844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of squamous cell carcinoma antigen-derived peptides having the capacity of inducing cancer-reactive CTLs in HLA-A24+ cancer patients.
    Homma S; Harada M; Yano H; Ogasawara S; Shichijo S; Matsueda S; Komatsu N; Shomura H; Maeda Y; Sato Y; Todo S; Itoh K
    Int J Oncol; 2006 Sep; 29(3):577-87. PubMed ID: 16865273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential CTLs specific for prostate-specific antigen in healthy donors and patients with prostate cancer.
    Elkord E; Williams PE; Kynaston H; Rowbottom AW
    Int Immunol; 2005 Oct; 17(10):1315-25. PubMed ID: 16141246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a novel tumor-associated antigen, cadherin 3/P-cadherin, as a possible target for immunotherapy of pancreatic, gastric, and colorectal cancers.
    Imai K; Hirata S; Irie A; Senju S; Ikuta Y; Yokomine K; Harao M; Inoue M; Tsunoda T; Nakatsuru S; Nakagawa H; Nakamura Y; Baba H; Nishimura Y
    Clin Cancer Res; 2008 Oct; 14(20):6487-95. PubMed ID: 18927288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate-specific antigen-derived epitopes capable of inducing cellular and humoral responses in HLA-A24+ prostate cancer patients.
    Harada M; Kobayashi K; Matsueda S; Nakagawa M; Noguchi M; Itoh K
    Prostate; 2003 Oct; 57(2):152-9. PubMed ID: 12949939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of hepatitis C virus (HCV) 2a-derived epitope peptides having the capacity to induce cytotoxic T lymphocytes in human leukocyte antigen-A24+ and HCV2a-infected patients.
    Wang Y; Takao Y; Harada M; Komatsu N; Ono T; Sata M; Itoh K; Yamada A
    Cell Immunol; 2006 May; 241(1):38-46. PubMed ID: 16963008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of parathyroid hormone-related protein-derived peptides immunogenic in human histocompatibility leukocyte antigen-A24+ prostate cancer patients.
    Yao A; Harada M; Matsueda S; Ishihara Y; Shomura H; Noguchi M; Matsuoka K; Hara I; Kamidono S; Itoh K
    Br J Cancer; 2004 Jul; 91(2):287-96. PubMed ID: 15199397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation of CA125-specific cytotoxic T lymphocytes in human leukocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.
    Bellone S; Anfossi S; O'Brien TJ; Cannon MJ; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    Am J Obstet Gynecol; 2009 Jan; 200(1):75.e1-10. PubMed ID: 18976739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HLA-A2-restricted cytotoxic T lymphocyte epitopes from human hepsin as novel targets for prostate cancer immunotherapy.
    Guo J; Li G; Tang J; Cao XB; Zhou QY; Fan ZJ; Zhu B; Pan XH
    Scand J Immunol; 2013 Sep; 78(3):248-57. PubMed ID: 23721092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a new shared HLA-A2.1 restricted epitope from the melanoma antigen tyrosinase.
    Riley JP; Rosenberg SA; Parkhurst MR
    J Immunother; 2001; 24(3):212-20. PubMed ID: 11394498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.